Cantor Fitzgerald Thinks This Pharma Stock Could Double

The analyst isn't concerned about UBX's trek to record lows

Digital Content Manager
Mar 7, 2019 at 12:55 PM
facebook twitter linkedin


The shares of Unity Biotechnology, Inc. (NASDAQ:UBX) suffered an 11.2% drop yesterday -- and touched a record low of $9.05 -- after poorly received fourth-quarter earnings. Despite all this, Cantor Fitzgerald last night initiated coverage of UBX with an "overweight" rating and a price target of $21 -- more than double the stock's current perch. The analyst waxed optimistic on Unity's "portfolio with multiple blockbusters," citing an increasing market for the company's age-related disease treatments. 

Cantor Fitzgerald is in good company, with three "buy" or better ratings and not a single "sell" for UBX. Plus, the analyst's $21 price target is still lower than the consensus 12-month target of $25.40 -- a roughly 173% premium to current levels. 

The stock was trading around $17 -- its initial public offering (IPO) price -- to start the year, but is down more than 42% year-to-date, amid pressure from its 20-day moving average. However, UBX today is up 2.4% at $9.30. 

UBX Chart March 7

Should Unity Biotechnology extend its bounce from new-low territory, a short squeeze could propel the stock higher. Currently, the 5.16 million UBX shares sold short represent a whopping 20.3% of the stock's available float. It would take over a month to buy back all these pessimistic positions, at the equity's average daily trading volume.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners